Get the Stockscreener App
2.48
5.08%
0.12
After Hours:
2.40
-0.08
-3.23%
Equillium Inc stock is traded at $2.48, with a volume of 261.16K.
It is up +5.08% in the last 24 hours and down -4.25% over the past month.
Equillium Inc is a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders with the mission to develop life-changing therapeutics for patients. It primary goal is to advance EQ504, a novel aryl hydrocarbon receptor, or AhR, modulator, into and through clinical development. The Company operates through a single operating and reportable segment focused on the business of developing novel therapies to treat severe autoimmune and inflammatory disorders, with the mission to develop life-changing therapeutics for patients. The Company manages all business activities on a consolidated basis.
See More
Previous Close:
$2.36
Open:
$2.262
24h Volume:
261.16K
Relative Volume:
0.31
Market Cap:
$157.25M
Revenue:
$4.39M
Net Income/Loss:
$-22.40M
P/E Ratio:
-4.8647
EPS:
-0.5098
Net Cash Flow:
$-22.79M
1W Performance:
+13.24%
1M Performance:
-4.25%
6M Performance:
+55.97%
1Y Performance:
+117.54%
1-Day Range:
$2.262
$2.49
1-Week Range:
$1.96
$2.49
52-Week Range:
$0.7562
$3.54
Equillium Inc Stock (EQ) Company Profile
Name
Equillium Inc
Sector
Industry
Phone
(858) 412-5302
Address
2223 AVENIDA DE LA PLAYA, LA JOLLA, CA
Compare EQ vs VRTX, REGN, ARGX, RVMD, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EQ
Equillium Inc
|
2.48 | 149.64M | 4.39M | -22.40M | -22.79M | -0.5098 |
VRTX
Vertex Pharmaceuticals Inc
|
515.55 | 128.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
805.93 | 82.72B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
987.84 | 53.26B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
212.00 | 43.66B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
362.51 | 39.31B | 5.76B | 514.49M | 1.10B | 4.4813 |
Equillium Inc Stock (EQ) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-23-26 | Initiated | Oppenheimer | Outperform |
| Apr-16-26 | Initiated | B. Riley Securities | Buy |
| Apr-14-26 | Initiated | Raymond James | Strong Buy |
| Apr-07-26 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-13-26 | Initiated | Roth Capital | Buy |
| Feb-25-26 | Initiated | Stifel | Buy |
| Mar-28-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Oct-29-21 | Resumed | Stifel | Buy |
| Sep-15-21 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-14-20 | Reiterated | H.C. Wainwright | Buy |
| Jul-10-20 | Resumed | Stifel | Buy |
| Feb-22-19 | Initiated | SVB Leerink | Outperform |
View All
Equillium Inc Stock (EQ) Latest News
Equillium (NASDAQ:EQ) Rating Increased to Hold at Wall Street Zen - MarketBeat
Oppenheimer Maintains Equillium(EQ.US) With Buy Rating, Maintains Target Price $7 - Moomoo
Roth MKM Maintains Equillium(EQ.US) With Buy Rating, Maintains Target Price $12 - Moomoo
Equillium (NASDAQ:EQ) Announces Earnings Results - MarketBeat
Equillium Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Form 8K Equillium Inc For: 13 August By Investing.com - Investing.com Nigeria
Equillium, Inc. Q2 2026: Net loss $(4.7)M, EPS $(0.04) — 10-Q Summary - TradingView
Equillium, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Affinity Asset Advisors reports 4.1M Equillium (EQ) shares, a 6.5% stake - Stock Titan
Equillium Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights - The Manila Times
Equillium (NASDAQ:EQ) Upgraded by Zacks Research to "Hold" Rating - MarketBeat
Equillium Inc (NASDAQ: EQ) Share Price, EQ Stock News, EQ Share Price & Updates - Kalkine
Adage Capital discloses 7.25% Equillium (EQ) stake via Schedule 13G/A filing - Stock Titan
EQ Q2'26 Earnings: EPS estimate is (0.05) USD - TradingView
Equillium Inc expected to post a loss of 5 cents a shareEarnings Preview - TradingView
Equillium, Inc. (NASDAQ:EQ) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Equillium Inc (EQ) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Equillium (EQ) Projected to Announce Earnings on Thursday - MarketBeat
EQ Q2'26 Earnings: revenue estimate is 0 USD - TradingView
Equillium, Inc. $EQ Holdings Lifted by Janus Henderson Group PLC - MarketBeat
Clear Street Maintains Equillium(EQ.US) With Buy Rating, Maintains Target Price $9 - Moomoo
Equillium Inc. (EQ) Shows Modest Gain as Shares Test Key ResistanceHigh Volume Node - dars.gov.et
ADAR1 Capital Management LLC Has $7.45 Million Position in Equillium, Inc. $EQ - MarketBeat
1,498,993 Shares in Equillium, Inc. $EQ Purchased by Eversept Partners LP - MarketBeat
EQ|Equillium Inc|Price:2.455|Chg%:-0.035 - TradingKey
Equillium Inc (EQ) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Equillium Inc (EQ) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Equillium Inc (EQ) Cash Flow - TradingKey
Equillium Inc (EQ) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
EQ|Equillium Inc|Price:2.490|Chg%:-0.200 - TradingKey
Equillium Inc (EQ) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
EQ|Equillium Inc|Price:2.580|Chg%:+0.090 - TradingKey
Equillium Inc (EQ) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
TradingKey - TradingKey
Equillium Inc (EQ) Balance Sheet - TradingKey
1,226,310 Shares in Equillium, Inc. $EQ Acquired by Affinity Asset Advisors LLC - MarketBeat
Analysts Are Bullish on These Healthcare Stocks: Equillium (EQ), CSL (CMXHF) - The Globe and Mail
Equillium Inc. (EQ) Q1 2026 Earnings: EPS Misses Estimate by 34.5%, Stock DeclinesROE Trend Analysis - dars.gov.et
Equillium (NASDAQ:EQ) Upgraded at Clear Str - MarketBeat
Equillium: The Market Seems To Have Already Priced In Phase 1 Success (NASDAQ:EQ) - Seeking Alpha
Clear Street Initiates Equillium(EQ.US) With Buy Rating, Announces Target Price $9 - Moomoo
Clear Street initiates Equillium stock with buy rating on IBD drug potential - Investing.com Nigeria
Equillium, Inc. (NASDAQ:EQ) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Equillium (NASDAQ:EQ) Rating Lowered to Strong Sell at Zacks Research - MarketBeat
Piper Sandler Initiates Equillium(EQ.US) With Buy Rating, Announces Target Price $20 - Moomoo
Equillium Q1 2026 Earnings: EPS Misses Estimates as Revenue Remains AbsentCash Flow Report - po-news-eg.net
EQUILLIUM INC : PIPER SANDLER INITIATES COVERAGE WITH OVERWEIGHT RATING; TARGET PRICE $20 - webull.com
Piper Sandler Initiates Coverage on Equillium With Overweight Rating, $20 Price Target - marketscreener.com
EQ Initiated Coverage by Piper SandlerRating Set to Overweigh - GuruFocus
Piper Sandler initiates Equillium stock with overweight rating - Investing.com
ETFs Investing in Equillium, Inc. Stocks - TradingView
Equillium Inc Stock (EQ) Financials Data
Revenue
Net Income
Cash Flow
EPS
Equillium Inc Stock (EQ) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Zedelmayer Christine | Sr. Vice President and COO |
Jun 05 '26 |
Option Exercise |
0.79 |
14,584 |
11,448 |
77,170 |
| Zedelmayer Christine | Sr. Vice President and COO |
Jun 05 '26 |
Sale |
2.93 |
14,584 |
42,737 |
62,586 |
| Connelly Stephen | President and CSO |
Jun 04 '26 |
Sale |
3.16 |
200,000 |
632,760 |
793,000 |
| Connelly Stephen | President and CSO |
Jun 05 '26 |
Sale |
2.94 |
30,975 |
91,070 |
762,025 |
1.80%
1.77%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):